Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 18,049,255	$ 7,830,855
Prepaid expenses and other	753,804	525,927
Total current assets	18,803,059	8,356,782
Other non-current assets:
Research and development supplies	1,503,207	1,802,228
Total other assets	1,503,207	1,802,228
Total assets	20,306,266	10,159,010
Current liabilities:
Accounts payables	1,655,028	743,070
Other current liabilities	1,698,468	1,431,564
Total current liabilities	3,353,496	2,174,634
Non-current liabilities:
Derivative liabilities	22,500	22,500
Total liabilities	3,375,996	2,197,134
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025	0	0
Common stock $0.001 par value: 200,000,000 shares authorized; 9,044,856 and 3,291,488 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	9,045	3,291
Additional paid-in capital	192,411,516	178,986,981
Accumulated deficit	(175,490,291)	(171,028,396)
Total stockholders’ equity	16,930,270	7,961,876
Total liabilities and stockholders’ equity	$ 20,306,266	$ 10,159,010

The amount of research and development assets classified as noncurrent.

No definition available.

Name:	gnpx_ResearchAndDevelopmentAssetsNoncurrent
Namespace Prefix:	gnpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.